QIC applies QUEST™ to build proprietary drug assets across radiopharmaceutical theranostics, peptide–drug conjugates and oral peptide therapeutics—from molecular design to preclinical validation and global partnering.
01 / PIPELINE ASSET PORTFOLIO
Each candidate is presented as a distinct development asset—with its own target, indication, modality, development stage and commercialization path.
| Asset | Indication | Modality | Discovery | Lead optimization | Preclinical | Clinical |
|---|---|---|---|---|---|---|
| Clear-cell renal cell carcinoma | RPT | PRECLINICAL · GLP PREPARATION | ||||
| Recurrent ovarian cancer · TNBC | PDC | LEAD OPTIMIZATION | ||||
| Metastatic melanoma · 2L+ | RPT | LEAD OPTIMIZATION | ||||
| Pan-cancer solid tumors | RPT | LEAD OPTIMIZATION | ||||
| Inflammatory bowel disease | ORAL PEPTIDE | LEAD OPTIMIZATION |
CA IX RPT is in preclinical development and GLP preparation. The other four programs are in lead optimization.
LEAD ASSET
Carbonic anhydrase IX-targeted radiopharmaceutical
Precision imaging and treatment through a tumor-selective CA IX ligand.
FOLLOW-ON ASSET
Carbonic anhydrase XII-targeted peptide–drug conjugate
A proprietary cyclic peptide platformed as a targeted drug-delivery asset.
RPT ASSET
Melanocortin 1 receptor-targeted radiopharmaceutical
Target-selective diagnosis and therapy for advanced melanoma.
RPT ASSET
Fibroblast activation protein-targeted radiopharmaceutical
A tumor-microenvironment strategy with multi-indication potential.
JOINT DEVELOPMENT
ORALINK-enabled oral cyclic peptide
An orally deliverable candidate built around a clinically validated target.
Stage labels reflect the current program status stated in QIC’s website and IR materials.
02 / PORTFOLIO ARCHITECTURE
QIC develops each asset through the modality best suited to its target biology and clinical opportunity, while QUEST™ provides the common molecular-design and evaluation system.
RPT / THERANOSTICS
Target-selective ligands are paired with diagnostic or therapeutic radioisotopes to connect tumor localization, patient selection and treatment.
PDC / TARGETED DELIVERY
A target-binding cyclic peptide serves as the delivery vehicle for a drug payload, extending QIC’s portfolio beyond radiopharmaceuticals.
ORAL PEPTIDE THERAPEUTICS
Structure-guided design is combined with oral-delivery technology to develop a differentiated peptide therapeutic.
03 / DEVELOPMENT & PARTNERING
QIC advances proprietary assets through computational design, experimental validation and preclinical development, with global licensing and co-development as the principal commercialization route.
Select a differentiated biological target and the modality best suited to its clinical opportunity.
Analyze target-ligand interaction and prioritize molecular structures for experimental testing.
Improve affinity, selectivity, drug properties and developability through iterative design.
Validate efficacy, biodistribution, pharmacokinetics and safety; prepare GLP and IND-enabling work where appropriate.
Pursue licensing or co-development when the program has achieved a defined evidence and value threshold.
Development plans and partnering points may differ by program and are subject to experimental results, regulatory requirements and partner strategy.
PIPELINE PARTNERSHIPS
QIC welcomes discussions with pharmaceutical companies, radiopharmaceutical specialists, research institutions and development partners.
Discuss a pipeline partnership